Ovascience Director Richard Aldrich Purchases 2,000 Shares (OVAS)
Ovascience (NASDAQ:OVAS) Director Richard Aldrich purchased 2,000 shares of the stock on the open market in a transaction that occurred on Tuesday, May 27th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $15,000.00. Following the completion of the acquisition, the director now directly owns 526,445 shares in the company, valued at approximately $3,948,338. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on OVAS shares. Analysts at HC Wainwright reiterated a “buy” rating on shares of Ovascience in a research note on Monday, May 12th. Separately, analysts at Oppenheimer initiated coverage on shares of Ovascience in a research note on Tuesday, April 29th. They set an “outperform” rating and a $11.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Ovascience to $16.00 in a research note on Thursday, April 3rd.
Shares of Ovascience (NASDAQ:OVAS) opened at 7.25 on Friday. Ovascience has a 52 week low of $5.509 and a 52 week high of $16.00. The stock has a 50-day moving average of $7.61 and a 200-day moving average of $8.98. The company’s market cap is $169.3 million.
Ovascience (NASDAQ:OVAS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.41) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.46) by $0.05. On average, analysts predict that Ovascience will post $-1.92 earnings per share for the current fiscal year.
OvaScience, Inc, is a life science company developing products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.